News

NX Prenatal Inc., a US based molecular diagnostics company utilizing its proprietary NeXosome® technology for early warning of adverse pregnancy outcomes, announced today that data from its ongoing validation studies will be presented at the Society of Maternal Fetal Medicine’s (SMFM) annual meeting held in Dallas, TX, January 29th through February 3rd, 2018.

NX Prenatal Inc. (“NX Prenatal”) today announced that its innovative technology would be presented at an upcoming conference in London, at the invitation of a Preterm Birth Working Group organized by the International Federation of Gynecology and Obstetrics (FIGO) and the March of Dimes (MOD).

NX Prenatal Inc., today announced the appointment of four industry experts to its Medical/Clinical Advisory Board, including: Kevin P. Rosenblatt, MD, PhD (NX Prenatal's CMO/CSO), Mary Lake Polan, MD, PhD, MPH (Chair Emeritus of Stanford University's Dept. of Obstetrics and Gynecology, and Clinical Professor in the Dept. of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine), Daniel W. Chan, PhD, DABCC, FACB (Director of the Johns Hopkins University Biomarker Discovery and Translation Center), and Thomas McElrath, MD, PhD, FACOG (Maternal-Fetal Medicine physician, Harvard Medical School Associate Professor of Obsetrics, Gynecology and Reproductive Biology, and Director of the Preterm Birth Clinic at Brigham & Women's Hospital).

NX Prenatal Inc., a privately held biotechnology company developing novel diagnostic tests in the women's health field, today announced the appointment of Kevin P. Rosenblatt, MD, PhD, as Chief Medical and Scientific Officer. In this role, Dr. Rosenblatt will bring his extensive experience in biomarker discovery, clinical proteomics, and clinical assay development to advance NXPN's proprietary pipeline of exosome-based diagnostic tests.

NX Prenatal, Inc. announced today that the American Journal of Obstetrics and Gynecology (“AJOG”) published a manuscript entitled, “Evaluation of proteomic biomarkers associated with circulating microparticles as an effective means to stratify the risk of spontaneous preterm birth,” from a clinical study evaluating blood-based biomarkers in pregnant mothers.

In a blinded peer-reviewed process, the Society for Maternal Fetal Medicine has selected our study titled “Circulating microparticles as an effective means to stratify the risk of spontaneous preterm birth” for oral presentation during its upcoming 36th Annual Pregnancy Meeting in Atlanta, GA.